← All trials
NCT01215149
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Dec 1, 2012
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 218
- Arms / groups
- 12 / —
- Source
- AACT · pre-existing
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- Aurum InstituteOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Desmond Tutu HIV FoundationOverall official - principal investigator
- Kenya AIDS Vaccine InitiativeOverall official - principal investigator
- HIV Vaccine Trials NetworkCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Ragon Institute of MGH, MIT and HarvardCollaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.